Company Overview and News
Shares of AbbVie, Inc. (ABBV - Free Report) fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions.
AMGN AGN UNP ABBV ABBV
Shares of Viking Therapeutics Inc. soared more than 87% yesterday on favorable top-line data from a phase II study, evaluating its novel liver-selective thyroid receptor beta agonist, VK2809, for treating non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
MDGL VKTXW AGN GILD CNAT ICPT VKTX
Prospects are looking brighter for Teva Pharmaceuticals Industries Limited (NYSE:TEVA). The company won a pair of FDA approvals in September. The big news here is the FDA approving its migraine treatment. Teva’s plan to shed assets from its Medis unit is another positive development, as the heavily indebted generics drug giant takes small steps to repair its business.
AGN TEVA BHC BHS
The acquisition was made to acquire a more potent, fast-acting facial treatment drug known as EB-001A.
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticals’s (ALNY) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation.
AGN KPTI THERF GSK PFE GSK BCDA ALNY
Allergan Plc (AGN - Free Report) announced that a study evaluating higher doses of its facial aesthetics drug Botox for the treatment of moderate-to-severe glabellar lines, met the primary endpoint.
AMGN AGN ACT
2018-09-14 channelnewsasia - 1
Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
RVNC AGN EOLS ACT
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) announced that the FDA has granted a fast track designation to its lead pipeline candidate, praliciguat, for the treatment of heart failure with preserved ejection fraction (HFpEF).
IRWD AGN BSTC PCRX
2018-09-14 reuters - 1
NEW YORK (Reuters) - Allergan Plc (AGN.N) said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
RVNC AGN EOLS ACT
NEW YORK, Sept 14 (Reuters) - Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
RVNC AGN EOLS ACT
Allergan Plc said it expects revenue at its medical aesthetics unit to grow to US$7 to US$8 billion by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
NEW YORK (Reuters) - Allergan Plc said it expects revenue at its medical aesthetics unit to grow to $7 to $8 billion by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
CY AGN GM
Allergan PLC [S: AGN] said on Friday that it will buy privately-held Bonti Inc. for an upfront payment of $195 million. Bonti makes substances that act on the nervous system called neurotoxins for cosmetic and medical uses. The agreement will give Allergan rights to two neurotoxin programs in phase 2 development, EB-001A, which is being developed for cosmetic purposes, and EB-001T, which is intended for medical use.
But for PMD, Big pharma drug makers and biotech continued to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.
GRFS ACET GILD AZN MCK CVS GSK SNY AZN AGN PMD NVS GSK ABBV CAH PFE ABBV
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to AGN / Allergan plc on message board site Silicon Investor.
as of ET